{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:30:24Z","timestamp":1787002224929,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:00:00Z","timestamp":1403654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:00:00Z","timestamp":1403654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/leu.2014.202","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T02:40:27Z","timestamp":1403664027000},"page":"474-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["CSNK1\u03b11 mediates malignant plasma cell survival"],"prefix":"10.1038","volume":"29","author":[{"given":"Y","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Cirstea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K C","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,25]]},"reference":[{"key":"BFleu2014202_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K . Multiple myeloma. N Engl J Medi 2011; 364: 1046\u20131060.","journal-title":"N Engl J Medi"},{"key":"BFleu2014202_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/asheducation-2011.1.184","volume":"2011","author":"KC Anderson","year":"2011","unstructured":"Anderson KC . New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program 2011; 2011: 184\u2013190.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu2014202_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R . Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508\u2013513.","journal-title":"Oncologist"},{"key":"BFleu2014202_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","volume":"2","author":"A Field-Smith","year":"2006","unstructured":"Field-Smith A, Morgan GJ, Davies FE .. Ther Clin Risk Manag 2006; 2: 271\u2013279.","journal-title":"Ther Clin Risk Manag"},{"key":"BFleu2014202_CR5","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1172\/JCI61188","volume":"122","author":"WM Kuehl","year":"2012","unstructured":"Kuehl WM, Bergsagel PL . Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456\u20133463.","journal-title":"J Clin Invest"},{"key":"BFleu2014202_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2011.53","volume":"25","author":"WJ Chng","year":"2011","unstructured":"Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026\u20131035.","journal-title":"Leukemia"},{"key":"BFleu2014202_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904\u2013917.","journal-title":"Cell"},{"key":"BFleu2014202_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/414768a","volume":"414","author":"A Trumpp","year":"2001","unstructured":"Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001; 414: 768\u2013773.","journal-title":"Nature"},{"key":"BFleu2014202_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature09673","volume":"470","author":"E Elyada","year":"2011","unstructured":"Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011; 470: 409\u2013413.","journal-title":"Nature"},{"key":"BFleu2014202_CR10","doi-asserted-by":"publisher","first-page":"9545","DOI":"10.1073\/pnas.1121119109","volume":"109","author":"M Toyoshima","year":"2012","unstructured":"Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 2012; 109: 9545\u20139550.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014202_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cellsig.2004.12.011","volume":"17","author":"U Knippschild","year":"2005","unstructured":"Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M . The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 2005; 17: 675\u2013689.","journal-title":"Cell Signal"},{"key":"BFleu2014202_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-09-2831","volume":"16","author":"NJ Dickens","year":"2010","unstructured":"Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010; 16: 1856\u20131864.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014202_CR13","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692\u20131700.","journal-title":"Blood"},{"key":"BFleu2014202_CR14","first-page":"508","volume":"28","author":"U Knippschild","year":"2005","unstructured":"Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Wurl PU et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 2005; 28: 508\u2013514.","journal-title":"Onkologie"},{"key":"BFleu2014202_CR15","doi-asserted-by":"publisher","first-page":"32384","DOI":"10.1074\/jbc.M109.052647","volume":"284","author":"AS Huart","year":"2009","unstructured":"Huart AS, MacLaine NJ, Meek DW, Hupp TR . CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem 2009; 284: 32384\u201332394.","journal-title":"J Biol Chem"},{"key":"BFleu2014202_CR16","doi-asserted-by":"publisher","first-page":"e43391","DOI":"10.1371\/journal.pone.0043391","volume":"7","author":"AS Huart","year":"2012","unstructured":"Huart AS, MacLaine NJ, Narayan V, Hupp TR . Exploiting the MDM2-CK1alpha protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One 2012; 7: e43391.","journal-title":"PLoS One"},{"key":"BFleu2014202_CR17","first-page":"1017","volume":"1","author":"DW Meek","year":"2003","unstructured":"Meek DW, Knippschild U . Posttranslational modification of MDM2. Mol Cancer Res 2003; 1: 1017\u20131026.","journal-title":"Mol Cancer Res"},{"key":"BFleu2014202_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.molcel.2005.06.024","volume":"19","author":"EC Alappat","year":"2005","unstructured":"Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE et al. Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 2005; 19: 321\u2013332.","journal-title":"Mol Cell"},{"key":"BFleu2014202_CR19","doi-asserted-by":"publisher","first-page":"23293","DOI":"10.1074\/jbc.270.40.23293","volume":"270","author":"R Beyaert","year":"1995","unstructured":"Beyaert R, Vanhaesebroeck B, Declercq W, Van Lint J, Vandenabele P, Agostinis P et al. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J Biol Chem 1995; 270: 23293\u201323299.","journal-title":"J Biol Chem"},{"key":"BFleu2014202_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1097-2765(01)00335-5","volume":"8","author":"S Desagher","year":"2001","unstructured":"Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001; 8: 601\u2013611.","journal-title":"Mol Cell"},{"key":"BFleu2014202_CR21","doi-asserted-by":"publisher","first-page":"30844","DOI":"10.1074\/jbc.M404651200","volume":"279","author":"Y Zhao","year":"2004","unstructured":"Zhao Y, Qin S, Atangan LI, Molina Y, Okawa Y, Arpawong HT et al. Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis. J Biol Chem 2004; 279: 30844\u201330849.","journal-title":"J Biol Chem"},{"key":"BFleu2014202_CR22","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1038\/bcj.2013.53","volume":"3","author":"Y Hu","year":"2013","unstructured":"Hu Y, Zheng M, Gali R, Tian Z, Topal Gorgun G, Munshi NC et al. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB\/c mice. Blood Cancer J 2013; 3: e156.","journal-title":"Blood Cancer J"},{"key":"BFleu2014202_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/gcc.20668","volume":"48","author":"L Agnelli","year":"2009","unstructured":"Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009; 48: 603\u2013614.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2014202_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/sj.embor.7400048","volume":"5","author":"G Rena","year":"2004","unstructured":"Rena G, Bain J, Elliott M, Cohen P . D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 2004; 5: 60\u201365.","journal-title":"EMBO Rep"},{"key":"BFleu2014202_CR25","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.yexcr.2008.06.011","volume":"314","author":"V Tillement","year":"2008","unstructured":"Tillement V, Lajoie-Mazenc I, Casanova A, Froment C, Penary M, Tovar D et al. Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization. Exp Cell Res 2008; 314: 2811\u20132821.","journal-title":"Exp Cell Res"},{"key":"BFleu2014202_CR26","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-07-6341","volume":"68","author":"L Moserle","year":"2008","unstructured":"Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 2008; 68: 5658\u20135668.","journal-title":"Cancer Res"},{"key":"BFleu2014202_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226\u2013231.","journal-title":"Nature"},{"key":"BFleu2014202_CR28","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1128\/MCB.00028-10","volume":"30","author":"N Reichert","year":"2010","unstructured":"Reichert N, Wurster S, Ulrich T, Schmitt K, Hauser S, Probst L et al. Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice, and for tumor suppression. Mol Cell Biol 2010; 30: 2896\u20132908.","journal-title":"Mol Cell Biol"},{"key":"BFleu2014202_CR29","first-page":"256","volume":"29","author":"TR Sana","year":"2005","unstructured":"Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK . Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 2005; 29: 256\u2013269.","journal-title":"Cytokine"},{"key":"BFleu2014202_CR30","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1038\/sj.onc.1208469","volume":"24","author":"DJ Dauer","year":"2005","unstructured":"Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005; 24: 3397\u20133408.","journal-title":"Oncogene"},{"key":"BFleu2014202_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/ng0797-260","volume":"16","author":"M Chesi","year":"1997","unstructured":"Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260\u2013264.","journal-title":"Nat Genet"},{"key":"BFleu2014202_CR32","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1182\/blood.V90.10.4062","volume":"90","author":"R Richelda","year":"1997","unstructured":"Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997; 90: 4062\u20134070.","journal-title":"Blood"},{"key":"BFleu2014202_CR33","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014; 123: 706\u2013716.","journal-title":"Blood"},{"key":"BFleu2014202_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0092-8674(00)81445-2","volume":"93","author":"J Zhu","year":"1998","unstructured":"Zhu J, Shibasaki F, Price R, Guillemot JC, Yano T, Dotsch V et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell 1998; 93: 851\u2013861.","journal-title":"Cell"},{"key":"BFleu2014202_CR35","doi-asserted-by":"publisher","first-page":"11757","DOI":"10.1074\/jbc.270.20.11757","volume":"270","author":"M Russell","year":"1995","unstructured":"Russell M, Lange-Carter CA, Johnson GL . Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1). J Biol Chem 1995; 270: 11757\u201311760.","journal-title":"J Biol Chem"},{"key":"BFleu2014202_CR36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-11-1789","volume":"18","author":"S Manni","year":"2012","unstructured":"Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A et al. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Clin Cancer Res 2012; 18: 1888\u20131900.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014202_CR37","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2005-11-013672","volume":"108","author":"FA Piazza","year":"2006","unstructured":"Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698\u20131707.","journal-title":"Blood"},{"key":"BFleu2014202_CR38","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood.V95.3.1039.003k02_1039_1046","volume":"95","author":"G Teoh","year":"2000","unstructured":"Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000; 95: 1039\u20131046.","journal-title":"Blood"},{"key":"BFleu2014202_CR39","first-page":"35","volume":"3","author":"K Oberg","year":"1992","unstructured":"Oberg K . The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992; 3: 35\u201341.","journal-title":"Semin Cancer Biol"},{"key":"BFleu2014202_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF02796202","volume":"17","author":"J Blade","year":"2000","unstructured":"Blade J, Esteve J . Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients? Med Oncol 2000; 17: 77\u201384.","journal-title":"Med Oncol"},{"key":"BFleu2014202_CR41","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","volume":"23","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333\u20136338.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014202","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:34:53Z","timestamp":1648730093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,25]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFleu2014202"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.202","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,25]]},"assertion":[{"value":"20 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}